Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR7106] to Retinoid X Receptor alpha/RXRA (HRP)
- Suitable for: WB
- Reacts with: Mouse, Rat, Human
- Conjugation: HRP
Product nameAnti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (HRP)
See all Retinoid X Receptor alpha/RXRA primary antibodies
DescriptionRabbit monoclonal [EPR7106] to Retinoid X Receptor alpha/RXRA (HRP)
Tested applicationsSuitable for: WBmore details
Unsuitable for: IHC-P
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human Retinoid X Receptor alpha/RXRA aa 1-100 (N terminal). The exact sequence is proprietary.
Database link: P19793
- WB: MCF7, HeLa, K562, RAW 264.7, PC12 and NIH 3T3 whole cell lysates.
This product was previously labelled as Retinoid X Receptor alpha
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. Store In the Dark.
Dissociation constant (KD)KD = 1.40 x 10 -12 M Learn more about KD
Storage bufferpH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: PBS, 1% BSA, 30% Glycerol
Concentration information loading...
PurityProtein A purified
- Signal Transduction
- Signaling Pathway
- Nuclear Signaling
- Nuclear Hormone Receptors
- Retinoic & Retinoid
Our Abpromise guarantee covers the use of ab200782 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/5000. Detects a band of approximately 51 kDa (predicted molecular weight: 51 kDa).|
FunctionReceptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid. RXRA serves as a common heterodimeric partner for a number of nuclear receptors. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. The RXRA/PPARA heterodimer is required for PPARA transcriptional activity on fatty acid oxidation genes such as ACOX1 and the P450 system genes.
Tissue specificityHighly expressed in liver, also found in lung, kidney and heart.
Sequence similaritiesBelongs to the nuclear hormone receptor family. NR2 subfamily.
Contains 1 nuclear receptor DNA-binding domain.
DomainComposed of three domains: a modulating N-terminal domain (AF1 domain), a DNA-binding domain and a C-terminal ligand-binding domain (AF2 domain).
modificationsPhosphorylated on serine and threonine residues mainly in the N-terminal modulating domain. Constiutively phosphorylated on Ser-21 in the presence or absence of ligand. Under stress conditions, hyperphosphorylated by activated JNK on Ser-56, Ser-70, Thr-82 and Ser-260 (By similarity). Phosphorylated on Ser-27, in vitro, by PKA. This phosphorylation is required for repression of cAMP-mediated transcriptional activity of RARA.
Sumoylation negatively regulates transcriptional activity. Desumoylated specifically by SENP6.
- Information by UniProt
- FLJ00280 antibody
- FLJ00318 antibody
- FLJ16020 antibody
All lanes : Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (HRP) (ab200782) at 1/1000 dilution
Lane 1 : MCF7 (Human breast adenocarcinoma cell line) Whole Cell Lysate
Lane 2 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
Lane 3 : K562 (Human erythromyeloblastoid leukemia cell line) Whole Cell Lysate
Lane 4 : RAW 264.7 (Mouse leukaemic monocyte macrophage cell line) Whole Cell Lysate
Lane 5 : PC12 (Rat adrenal pheochromocytoma cell line) Whole Cell Lysate
Lane 6 : NIH 3T3 (Mouse embryonic fibroblast cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 51 kDa
Observed band size: 51 kDa
Exposure time: 12 minutes
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab200782 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab200782 has not yet been referenced specifically in any publications.